The Administrative Core (Core A) will direct and coordinate several major areas contributing to the activities of the Combination HIV Antiretroviral Rectal Microbicide or CHARM Program. These activities include (1) administrative oversight of the entire program including all Projects and Cores, (2) providing financial oversight of the program, (3) act as primary liaison with the NIAID/DAIDS appointed Program Officer with responsibility for the Integrated Preclinical/Clinical Program for HIV Topical Microbicides U19 Program, (4) coordinate the monthly conference calls for the Steering Committee (SC) and disseminate agendas / meeting minutes in a timely fashion, (5) organize the annual IP/CP meeting, (5) in collaboration with NIAID/DAIDS, establish and provide logistical support for a Scientific Advisory Panel facilitation, and (6) undertake website maintenance, education, publication assistance, library maintenance, and general administrative support. The Core will link the various project leaders and programs as well as integrate the related milestones of each project and ensuring communication between project leaders. The SC, composed of the Principal Investigator and each Project Leader/Associate-Leader, Core Leader/Associate Leader, and select key personnel, will be the central mechanism in assuring communication between Projects, Project sites, and Cores. The Administrative Core will also produce twice-yearly internal progress reports for the SC. These will be available to interested key personnel and the NIH's Scientific Advisory Panel (SAP).

Public Health Relevance

The Administrative Core will be the primary mechanism to provide administrative, logistical, and financial support for the Projects and Cores as they work towards the achievement of their milestones in pursuit of a combination antiretroviral rectal microbicide

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI082637-05
Application #
8722091
Study Section
Special Emphasis Panel (ZAI1-BP-A (J1))
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2013
Total Cost
$188,740
Indirect Cost
$21,761
Name
Magee-Women's Research Institute and Foundation
Department
Type
DUNS #
119132785
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Richardson-Harman, Nicola; Parody, Robert; Anton, Peter et al. (2017) Analytical Advances in the Ex Vivo Challenge Efficacy Assay. AIDS Res Hum Retroviruses 33:395-403
Chiu, Wai Kan; Brand, Rhonda M; Camp, Danielle et al. (2017) The Safety of Multiple Flexible Sigmoidoscopies with Mucosal Biopsies in Healthy Clinical Trial Participants. AIDS Res Hum Retroviruses 33:820-826
Hladik, Florian; Burgener, Adam; Ballweber, Lamar et al. (2015) Mucosal effects of tenofovir 1% gel. Elife 4:
Hiruy, Hiwot; Fuchs, Edward J; Marzinke, Mark A et al. (2015) A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02). AIDS Res Hum Retroviruses 31:1098-108
Mcgowan, Ian; Cranston, Ross D; Duffill, Kathryn et al. (2015) A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study). PLoS One 10:e0125363
Wahl, Angela; Victor Garcia, J (2014) The use of BLT humanized mice to investigate the immune reconstitution of the gastrointestinal tract. J Immunol Methods 410:28-33
McGowan, Ian (2014) The development of rectal microbicides for HIV prevention. Expert Opin Drug Deliv 11:69-82
Dezzutti, Charlene S; Russo, Julie; Wang, Lin et al. (2014) Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation. PLoS One 9:e102585
McGowan, Ian; Dezzutti, Charlene (2014) Rectal microbicide development. Curr Top Microbiol Immunol 383:117-36
Rohan, Lisa C; Yang, Haitao; Wang, Lin (2013) Rectal pre-exposure prophylaxis (PrEP). Antiviral Res 100 Suppl:S17-24

Showing the most recent 10 out of 24 publications